New hope against drug-resistant lung bug: contezolid shows early promise
NCT ID NCT07372781
First seen Feb 01, 2026 · Last updated Apr 28, 2026 · Updated 7 times
Summary
This study tests a new antibiotic called contezolid in 24 adults with a stubborn lung infection caused by Mycobacterium abscessus. Participants take the drug alone for 14 days, and researchers measure how much the bacteria level drops in their sputum compared to a standard antibiotic. The goal is to see if contezolid can become a new treatment option for this difficult infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM ABSCESSUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing chest hospital affiliated to Capital medical university, Beijing Tuberculosis & Thoracic Tumor Research Institute
Beijing, Beijing Municipality, 101149, China
Conditions
Explore the condition pages connected to this study.